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Background: Glucocorticoid (GC) therapy is associated with an increased risk of fractures. The main objective of this
study was to determine the prevalence of undiagnosed vertebral fractures in women chronically using GC therapy for
autoimmune disorders. We also determined the prevalence of non-vertebral fractures, and investigated whether factors
such as quality-of-life and future fracture risk are associated with vertebral/non-vertebral fractures.
Methods: This was a multicenter cross-sectional study conducted in Spain. All women had rheumatoid arthritis (RA)
and/or systemic lupus erythematosus (SLE). Radiological morphometric vertebral fractures were evaluated centrally
(Genant semiquantitative method), whereas non-vertebral fractures were not assessed by radiography. Before
radiography, patients were asked whether they had vertebral/non-vertebral fractures, hereafter referred to as
‘self-reported’ fractures. Assessment tools included the Disease Activity Score (DAS28), the SF-36 questionnaire,
and FRAX®.
Results: Complete data were obtained for 576 outpatients with RA and/or SLE (83.3 % had RA); mean [SD] age
59.6 [15] years. Of all patients, 6.4 % had self-reported vertebral fractures, whereas 18.9 % had morphometric
vertebral fractures (RA: 7.1 % self-reported vs. 20.0 % morphometric; SLE: 3.2 % self-reported vs. 13.7 % morphometric).
Non-vertebral fractures were self-reported by 9.8 % of RA and 5.3 % of SLE patients. Low physical functioning was
associated with morphometric vertebral fractures (mean [SD] SF-36 score 18.8 [6.0] when present vs. 20.1 [5.9]
when absent; p = 0.028) and self-reported non-vertebral fractures (16.7 [5.2] when present vs. 20.1 [5.9] when
absent; p < 0.001). Mean [SD] DAS28 was higher (p = 0.013) when any self-reported fractures were present (4.0
[1.3]) than absent (3.6 [1.3]). Based on FRAX® analysis, patients with vs. without morphometric vertebral fractures
had higher 10-year probabilities of major osteoporotic fractures (mean [SD] 17.9 [12.9]% vs. 9.9 [9.6]%; p < 0.001)
and hip fractures (11.0 [11.7]% vs. 4.6 [8.1]%; p < 0.001).
Conclusions: Morphometric vertebral fractures were detected in 18.9 % of patients, i.e. 3-times more frequently
than verbally reported by patients. Patients with vs. without fractures had worse quality-of-life and increased
fracture risk. Accordingly, it is of utmost importance that women chronically using GCs are assessed for fractures,
including morphometric vertebral fractures.
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Glucocorticoid (GC) medications are widely used to
treat various inflammatory and autoimmune disorders,
including rheumatoid arthritis (RA) and systemic lupus
erythematosus (SLE). Community surveys indicate that
0.2 to 0.5 % of the general population may receive GC
therapy [1]. However, GC therapy is associated with in-
creased risk of fractures, elevated by as much as 75 %
within the first 3 months of treatment [2], and rapid de-
crease in bone mineral density (BMD) and trabecular
bone volume (TBV), e.g. a 25 % reduction in TBV has
been observed after 5–7 months of GC therapy [3].
While GC treatments are the most common cause of
secondary osteoporosis [1], they may also increase the
risk of fractures by triggering deterioration of bone qual-
ity. This may explain why Van Staa et al. [4] demon-
strated that postmenopausal women taking GCs had
more than twice the risk of fracture versus women not
taking GCs, even though the GC users had higher BMD
than the controls.
With regard to the type of fractures that commonly
occur in patients using GC therapy and/or diagnosed
with RA/SLE, vertebral fractures are of particular inter-
est. This is not only due to the high prevalence of verte-
bral fractures in patients with RA (15–36 %) [5–8], and
in patients with SLE (20-50 %) [9–13], but also the great
impact that these fractures have on quality-of-life (QoL;
including physical functioning) [5, 14, 15], mortality
[16–18], and the risk of future fractures [19]. Patients
with vertebral fractures may also suffer from long-term
back pain [20]. It is therefore notable that vertebral frac-
tures are often asymptomatic or mild-to-moderately
symptomatic [2, 21, 22]; thus, under-diagnosis [9, 22, 23]
and under-treatment [24] are major problems. For ex-
ample, vertebral fractures were detected by X-rays in
14.1 % of 934 women admitted to hospital (for reasons
not related to osteoporosis), whereas only 1.8 % of the
934 patients were diagnosed with vertebral fractures
without X-ray analysis [25]. Similarly, Angeli et al. [21]
found that ultrasound and BMD measurements were
ineffective for predicting the number and severity of ver-
tebral fractures in women undergoing GC therapy; thus,
appropriate diagnostic procedures and physician aware-
ness of the risk of fractures are paramount to identify
and treat patients at high risk [2].
Few studies have investigated the prevalence of frac-
tures in Spanish patients receiving chronic GC therapy.
Accordingly, the primary objective of this study was to
determine the prevalence of undiagnosed vertebral frac-
tures in women chronically using GC therapy for auto-
immune disorders in Spain. To meet this objective,
patients were asked whether or not they had any vertebral
fractures, hereafter referred to as ‘self-reported’ fractures,
and their prevalence was compared to the prevalence ofvertebral fractures subsequently identified by radiography.
The key secondary objective was to determine the preva-




Female outpatients aged ≥18 years, diagnosed with RA
and/or SLE for more than 1 year, taking GC treatment
(dose ≥2.5 mg of prednisone, or equivalent) for at least
3 months. At least 4 of 7 criteria had to be present for a
diagnosis of RA [26], whereas at least four of 11 criteria
had to be present for a diagnosis of SLE [27]. Patients
had to be willing to undergo lateral thoracic and lumbar
spine X-rays.
Exclusion criteria
The most clinically relevant exclusion criteria were: a
diagnosis of metabolic bone disease, excluding osteopor-
osis, but including any active neoplastic disease; preg-
nancy at the time of radiological assessment. The other
exclusion criteria were: the patient being an employee of
the study sponsor, or being investigator site personnel
directly affiliated with the study or their immediate fam-
ily (spouse, parent, child, or sibling); current enrollment
in or discontinuation from a clinical trial in the last
30 days, or concurrent enrollment in any other type of
medical research that was judged as not being scientific-
ally or medically compatible with this study.
Objectives
The primary objective of this study was to determine the
prevalence of undiagnosed vertebral fractures in women
receiving chronic GC therapy. The key secondary object-
ive was to determine the prevalence of self-reported
non-vertebral fractures in these patients. Other second-
ary objectives were to assess potential relationships
between the presence/absence of fractures and the fol-
lowing variables: patient characteristics; the presence of
other diseases affecting bone metabolism; cumulative
GC dose (prednisone 5 mg or equivalent for other GCs,
received during the last 10 years, including intravenous
pulses); disease activity and disability with RA, using
the Disease Activity Score (DAS28) [28], and the Span-
ish 20-item Health Assessment Questionnaire (HAQ)
[29]; Health-Related Quality-of-Life (HRQoL), using the
SF-36 questionnaire; the 10-year risk of a major osteopor-
otic fracture or a hip fracture, using the fracture risk-
assessment tool (FRAX®, available at http://www.shef.ac.
uk/FRAX/); treatments to reduce bone loss.
Study design
This was a population-based, cross-sectional, outpatient
study conducted at 28 centers in Spain between June
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sample of the Spanish patient population, the participat-
ing sites were proportionally selected from Autonomous
Communities throughout Spain, according to overall
population figures published by the National Statistics
Institute (INE) in January 2008. The study was approved
by the responsible institutional review board at each
study site,1 and was conducted in accordance with the
ethical principles of the Declaration of Helsinki, good
clinical practice guidelines, and applicable laws and
regulations.
Patients attended their rheumatologist’s office for any
reason, and following informed consent could be in-
cluded in this study. Each rheumatologist recruited pa-
tients consecutively. All data that had to be verbally
collected from the patient, i.e. on the nature of vertebral
and non-vertebral fractures, and on HRQoL, as well as
X-rays, were collected during this single visit at the
rheumatologist’s office.
Fracture assessments
Vertebral fractures were detected using X-rays, evaluated
by a central reader using the Genant semiquantitative
method [30]. A morphometric radiological vertebral
fracture was defined as at least a 20 % reduction (at least
4 mm) in anterior, middle, and/or posterior vertebral
height, and a change of at least a 1-degree angle accord-
ing to the semiquantitative assessment. According to
semiquantitative endpoints, the severity of each vertebral
fracture is defined as grade 0 (no fracture), grade 1
(mild), grade 2 (moderate), or grade 3 (severe), based on
the reduction in vertebral height. Normal vertebrae
(grade 0) show minimal deformity, with a <20 % reduc-
tion in anterior, middle, and posterior vertebral height.
Mild vertebral deformity (grade 1) is defined as a re-
duction of 20–25 % in vertebral height. Moderate
(grade 2) and severe (grade 3) vertebral fractures are re-
spectively defined as reductions of 25–40 % and >40 %
in vertebral height.
Before radiography, the rheumatologists asked their
patients whether or not they had any vertebral or non-
vertebral fractures (the latter in the proximal femur,
humerus, distal radius, sternum/ribs, tibia, pelvis, di-
aphyseal femur, distal femur); we refer to these as ‘self-
reported’ fractures.
Statistical analysis
To estimate the prevalence of vertebral and non-vertebral
fractures with a precision of ±3.5 %, expressed as 95 %
confidence intervals (CIs), and with a significance level of
5 %, a study population of 587 patients was needed.
Assuming that 5 % of the sample would be non-evaluable
due to screening failures, the minimum sample size for
screened patients was 618 patients.Primary analysis
The number and percentage of women with morpho-
metric vertebral fractures were determined overall
(i.e. for all patients) and by diagnosis (i.e. RA or SLE),
based on X-ray data. The number and percentage of
women with self-reported vertebral fractures were also
summarized overall and by diagnosis. However, the total
number of vertebral fractures, their location (lumbar/
thoracic), and severity (mild/moderate/severe) were only
determined using X-ray data, and not based on self-
reports.
Key secondary analysis
The number and percentage of patients with, and the
total number of, self-reported non-vertebral fractures
were summarized overall, by diagnosis, and by fracture
location (e.g. distal radius, proximal femur, rib).
Statistical methods, used to compare the following
variables in the presence and absence of vertebral and/
or non-vertebral fractures, included: t-test for DAS28,
HAQ, FRAX®, and HRQoL; Kruskal-Wallis test for non-
normally distributed variables (patient demographics
and cumulative GC dose); and, as a supportive analysis
for cumulative GC dose, analysis of covariance (ANCOVA)
adjusted for 9 covariates. The ANCOVA covariates were
selected by medical judgment, and comprised: age, body
mass index (BMI), menopausal status, diagnosis (RA or
SLE), presence of disease affecting bone metabolism,
exposure to therapies associated with risk of fracture,
current GC dose, smoking status, and whether the patient’s
parent had sustained a hip fracture. All statistical tests are
exploratory, and significance was set at p < 0.05 (2-sided).
No imputations of missing values and no multiplicity
adjustments were performed. Data were analyzed using
SAS software© version 8.2.
Results
Patient disposition and baseline demographics
Of the 605 screened outpatients, 576 met all eligibility
criteria and were included in this cross-sectional study.
One patient was withdrawn due to physician decision
before being X-rayed, although their data were included
in the self-reported fracture analysis. As shown in Fig. 1,
480 (83.3 %) patients had RA and 95 (16.5 %) patients
had SLE. The patients with RA were older (mean [SD]
age 62.4 [13.5] years) than the patients with SLE (45.8
[14.6] years),2 while the time from diagnosis was similar
in the 2 groups (Fig. 1).
Prevalence of vertebral fractures
As expected, the prevalence of morphometric vertebral
fractures was higher than the prevalence of self-reported
vertebral fractures in patients with RA, SLE, and overall
(i.e. for all patients). Specifically, the numbers (proportion
Fig. 1 Patient disposition and baseline demographics. BMI: body mass index; GC: glucocorticoid; N: total number of patients in group; RA: rheumatoid
arthritis; SD: standard deviation; SLE: systemic lupus erythematosus. a 1 patient was diagnosed with RA and SLE and is included in both groups. b 2 patients
were diagnosed with RA and/or SLE, although this diagnostic information was missing when the data was analyzed. These 2 patients were included in the
analysis
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vertebral fracture vs. self-reported vertebral fracture were:
109 (18.9 %, 15.8-22.4) vs. 37 (6.4 %, 4.6–8.7) overall, 96
(20.0 %, 16.5–23.9) vs. 34 (7.1 %, 5.0–9.8) in RA patients,
and 13 (13.7 %, 7.5–22.3) vs. 3 (3.2 %, 0.7–9.0) in SLE pa-
tients2 (Fig. 2). Only 3 of the 37 patients with self-reported
vertebral fractures did not have these fractures confirmed
in the morphometric radiological assessments. In the mor-
phometric radiological assessments, 235 vertebral frac-
tures were detected in the 109 patients; the locations and
severity of these fractures were similar in patients with RA
vs. those with SLE (Table 1).
Patient characteristics by morphometric vertebral fracture
status
Patients with morphometric vertebral fractures (N = 109)
were statistically significantly older (mean [SD] 69.7 [10.8]
vs. 57.3 [14.9] years) than those without fractures (N = 467),
had a longer time since menopause (22.4 [10.1] vs. 16.7Fig. 2 Estimated proportions of patients with vertebral fractures. N: total
number of patients in group; RA: rheumatoid arthritis; SLE: systemic lupus
erythematosus. a Total number of patients with/without fractures[10.5] years), and shorter height (155.9 [7.6] vs. 158.7 [7.0]
cm) (p < 0.001 for all 3 parameters; Table 2).
Prevalence of self-reported non-vertebral fractures
The prevalence of patients with at least 1 self-reported
non-vertebral fracture2, and the number and locations of
self-reported non-vertebral fractures in these patients,
are shown in Table 1. For RA, the most common loca-
tions of self-reported non-vertebral fractures were: 17
(28.8 %) in the distal radius, and 13 (22.0 %) in the prox-
imal femur. For SLE, the most common self-reported
non-vertebral fracture locations were 3 (33.3 %) in the
rib, and 2 (22.2 %) in the distal radius.
Diseases affecting bone metabolism
Similar proportions of patients with versus without mor-
phometric vertebral fractures, or with versus without
self-reported non-vertebral fractures, had at least 1 dis-
ease affecting bone metabolism. Specifically, 7 (6.4 %) of
109 patients with and 29 (6.2 %) of 467 patients without
morphometric vertebral fractures, and 3 (6.5 %) of 46
patients with and 33 (6.3 %) of 530 patients without self-
reported main non-vertebral fractures had at least 1 dis-
ease affecting bone metabolism. Diseases affecting bone
metabolism in >1 % of patients were: secondary amenor-
rhea (duration >1 year), hyperthyroidism, type I diabetes,
liver disease, and urolithiasis.
Cumulative GC dose
In patients with versus without morphometric vertebral
fractures, cumulative GC dose and time from the start
of GC use were not significantly different, despite being
Table 1 The prevalence of morphometric vertebral fractures and self-reported non-vertebral fractures
Overall Patients with RA Patients with SLE
N = 576 N = 480 N = 95
Vertebral fractures:
Patients (%) with at least 1 vertebral fracture 109 (18.9) 96 (20.0) 13 (13.7)
Number of vertebral fractures (%) 235 (100.0) 203 (100.0) 32 (100.0)
Thoracic 159 (67.7) 135 (66.5) 24 (75.0)
Lumbar 76 (32.3) 68 (33.5) 8 (25.0)
Mild 124 (52.8) 105 (51.7) 19 (59.4)
Moderate 76 (32.3) 68 (33.5) 8 (25.0)
Severe 35 (14.9) 30 (14.8) 5 (15.6)
Non-vertebral fractures:
Patients (%) with at least 1 non-vertebral fracture 52 (9.0) 47 (9.8) 5 (5.3)
Number of non-vertebral fractures (%) 68 (100.0) 59 (100.0) 9 (100.0)
Proximal femur 14 (20.6) 13 (22.0) 1 (11.1)
Proximal humerus 8 (11.8) 8 (13.6) 0
Distal radius 19 (27.9) 17 (28.8) 2 (22.2)
Rib 7 (10.3) 4 (6.8) 3 (33.3)
Tibia 4 (5.9) 3 (5.1) 1 (11.1)
Pelvis 5 (7.4) 5 (8.5) 0
Othera 11 (16.2) 9 (15.3) 2 (22.2)
N total number of patients in group, RA rheumatoid arthritis, SLE systemic lupus erythematosus
aNo fractures were reported in the distal femur, diaphyseal femur, or sternum
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ment for selected baseline variables,3 no statistically sig-
nificant difference (p = 0.087) was detected in cumulative
GC dose in the presence versus absence of morphomet-
ric vertebral fractures; however, cumulative GC dose was
about 40 % higher (p = 0.026) for patients with versus
those without self-reported vertebral fractures, after the
adjustment.
In the presence versus absence of any self-reported
main non-vertebral fractures, cumulative GC dose was
higher (mean [SD] 28.6 [32.1] vs. 14.4 [16.7] g; N = 46
vs. N = 527; p < 0.001), and time from the start of GC
use was longer (12.8 [8.7] vs. 6.9 [5.6] years; N = 46 vs.
N = 528; p < 0.001). Likewise, following adjustment for
selected baseline variables3, cumulative GC dose was
about 70 % higher (p < 0.001) in patients with versus those
without any self-reported main non-vertebral fractures.
Relationships between RA and fracture status
DAS28 scores were higher (mean [SD] 4.0 [1.3] vs. 3.6
[1.3]; p = 0.013) when any self-reported fractures were
present (N = 73) than in their absence (N = 407), indicat-
ing that RA was more active in the presence of self-
reported fractures. Similarly, the presence of self-reported
fractures (i.e. any fractures, vertebral fractures, main non-
vertebral fractures; p < 0.001 for all 3 groups) wasassociated with greater disability, as shown by higher
HAQ scores than in RA patients without fractures
(Fig. 3). The presence of morphometric vertebral frac-
tures was also associated with greater disability in RA
patients than in the absence of fractures (p = 0.011),
although less so than for patients with self-reported
vertebral fractures (Fig. 3).
Health-related quality-of-life
SF-36 physical component scores were statistically sig-
nificantly lower for patients with versus without self-
reported vertebral fractures (mean [SD] 30.5 [16.5] vs.
41.3 [19.8]; N = 37 vs. N = 536; p < 0.001), and also for
patients with versus without self-reported main non-
vertebral fractures (mean [SD] 31.7 [21.4] vs. 41.4 [19.4];
N = 46 vs. N = 527; p < 0.001). Of the SF-36 subscores for
the physical component, low physical functioning and
role limitation due to physical problems were both
statistically significantly associated with self-reported
vertebral fractures and self-reported main non-vertebral
fractures (data not shown). Of all SF-36 scores, only the
low physical functioning SF-36 subscore was statistically
significantly associated with morphometric vertebral
fractures, with lower scores in their presence versus
absence (mean [SD] 18.8 [6.0] vs. 21.1 [5.9]; N = 108 vs.
N = 465; p = 0.028).




N = 576 N = 109 N = 467
Age, years
Mean (SD) 59.6 (15.00) 69.7 (10.81) 57.3 (14.88)
P-valueb <0.001
BMI, kg/m2
Mean (SD) 26.8 (4.83) 26.6 (3.61) 26.9 (5.08)
P-valueb 0.724
Race, n (%)
Caucasian 566 (98.3) 109 (100) 457 (97.9)
Black 3 (0.5) 0 (0.0) 3 (0.6)
American Indian or Alaska native 5 (0.9) 0 (0.0) 5 (1.1)
Other 2 (0.3) 0 (0.0) 2 (0.4)
Menopause, n (%)
Started 422 (73.3) 104 (95.4) 318 (68.1)
Started at age ≤40 37 (6.4) 11 (10.1) 26 (5.6)
Not started 150 (26.0) 4 (3.7) 146 (31.3)
Unknown 4 (0.7) 1 (0.9) 3 (0.6)
Time since menopause, years
Mean (SD) 18.1 (10.66) 22.4 (10.06) 16.7 (10.47)
P-valueb <0.001
Height, cm
Mean (SD) 158.2 (7.20) 155.9 (7.61) 158.7 (7.00)
P-valueb <0.001
Cumulative GC dose, g
Mean (SD) 15.5 (18.77) 18.3 (23.00) 14.9 (17.63)
P-valueb 0.346
Time from the start of GC use, years
Mean (SD) 7.4 (6.15) 8.4 (7.60) 7.1 (5.74)
P-valueb 0.279
Percentage of patients taking calcium and/or vitamin D 49.3 52.3 48.6
Calcium 45.0 49.5 43.9
Vitamin D 45.0 51.4 43.5
Percentage of patients taking bisphosphonates 42.7 66.1 37.3
Alendronate 20.3 32.1 17.6
Risedronate 16.5 22.9 15.0
Ibandronate 9.7 19.3 7.5
Zoledronic acid 1.2 2.8 0.9
Percentage of patients taking other medications
Strontium ranelate 2.3 3.7 1.9
Teriparatide 1.9 6.4 0.9
Raloxifine 1.2 2.8 0.9
BMI body mass index, GC glucocorticoid, n number of patients, N total number of patients in group, SD standard deviation
aTreatments to reduce bone loss used by ≥1.2 % of the overall population
bP-value is for the difference between the 2 fracture cohorts, calculated using Kruskal-Wallis test
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Fig. 3 Disability vs. fracture status in patients with RA. HAQ: Spanish 20-item Health Assessment Questionnaire; N: total number of patients in group;
RA: rheumatoid arthritis; SD: standard deviation. a Statistically significantly different mean HAQ scores by fracture status, calculated using t-test. b Total
number of RA patients with/without fractures
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In the FRAX® analysis, patients who already had a mor-
phometric or self-reported vertebral fracture, or self-
reported non-vertebral fracture, had statistically sig-
nificantly higher 10-year probabilities of sustaining a
major osteoporotic fracture or hip fracture than pa-
tients without fractures. For example, mean (SD) risk
of sustaining a major osteoporotic fracture was 17.9 %
(12.92) for patients with morphometric vertebral frac-
tures (N = 106) vs. 9.9 % (9.64) for patients without
these fractures (N = 469; p < 0.001).
Treatment to reduce bone loss
Higher proportions of patients with versus without
morphometric vertebral fractures (81.7 % vs. 63.2 %),
self-reported vertebral fractures (97.3 % vs. 64.6 %), and
self-reported main non-vertebral fractures (95.7 % vs.
64.2 %) were receiving treatment to reduce bone loss.
For each type of fracture, the main treatments used to
reduce bone loss were vitamin D, calcium, bisphospho-
nates, strontium ranelate, teriparatide, and raloxifine.
The proportions of patients with versus without mor-
phometric vertebral fractures using these medications
are shown in Table 2. The proportions of patients with
versus without self-reported vertebral fractures receiv-
ing medication were 89.2 % vs. 39.5 % (bisphospho-
nates), 52.3 % vs. 48.6 % (vitamin D and/or calcium),
16.2 % vs. 0.9 % (teriparatide), 8.1 % vs. 0.7 % (raloxi-
fen), and 5.4 % vs. 2.0 % (strontium ranelate). The pro-
portions of patients with versus without self-reported
main non-vertebral fractures receiving medication were
82.6 % vs. 39.2 % (bisphosphonates), 65.2 % vs. 47.9 %
(vitamin D and/or calcium), 10.9 % vs. 1.1 % (teripara-
tide), 6.5 % vs. 0.8 % (raloxifen), and 10.9 % vs. 1.5 %
(strontium ranelate).Discussion
In this population-based, cross-sectional study, centralized
X-ray assessment increased the detection rate of vertebral
fractures to 18.9 %, from 6.4 % for self-reported vertebral
fractures, in women with RA and/or SLE receiving
chronic GC therapy. This finding is consistent with other
reports suggesting that vertebral fractures are under-
diagnosed in post-menopausal women [21, 23, 25]. These
reports included a cross-sectional study by Angeli et al.
[21] in which patients (N = 551) received chronic GC ther-
apy, and had RA, SLE, asthma/chronic obstructive
pulmonary disease, rheumatic polymyalgia, or another
vasculitis or connective tissue disease. Moreover, in a sam-
ple of 2451 post-menopausal women with osteoporosis, in
the IMPACT study, under-diagnosis of vertebral fractures
was shown to be a worldwide problem (false-negative
rates: North America, 45.2 %; Latin America, 46.5 %;
Europe/South Africa/Australia, 29.5 %) [23].
In our study, 85.1 % of vertebral fractures detected in
centrally assessed X-rays were mild-to-moderate in se-
verity, compatible with the high prevalence (37 %) of
asymptomatic vertebral fractures in GC-users reported
by Angeli et al. [21]. In addition, in our study, vertebral
and non-vertebral fractures had a detrimental impact on
patients’ lives, relative to patients without these frac-
tures. This included greater disability and reduced phys-
ical functioning in women with RA and/or SLE who had
self-reported or morphometric fractures. Likewise, RA/
SLE patients with self-reported or morphometric verte-
bral fractures had a higher 10-year risk of suffering from
a major osteoporotic fracture or hip fracture, compared
with patients without fractures, as determined by FRAX®
analysis. A similar finding of increased 10-year risk of
fractures in patients with SLE versus healthy controls
was recently reported by Mak et al. [31].
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role limitation due to physical problems, and the 10-year
risk of fracture, appeared to be particularly high for
patients with self-reported vertebral fractures versus
morphometric vertebral fractures. Together with the
higher prevalence of morphometric than self-reported
vertebral fractures (18.9 % vs. 6.4 %), overall these data
suggest that the morphometric fractures may have been
milder than the self-reported fractures.
Vertebral fractures appeared to be prevalent in RA
and SLE patients, being detected in 20 % of patients with
RA and 13.7 % of patients with SLE by centralized X-ray
assessment. Although, as the RA patients were older
than the SLE patients, and age influences fracture risk,
no direct comparison of fracture prevalence should be
made between these 2 patient groups, and these data
should only act as an indicator of the high prevalence of
vertebral fractures in these patients. Similarly high preva-
lence rates of vertebral fractures, detected in X-rays, have
previously been found in studies of RA (15–36 % of 97–
275 patients) [5–8] and SLE (20–50 % of 52–210 patients)
[9–13]. The number of patients with self-reported non-
vertebral fractures in our cross-sectional study (found in
9.8 % of RA and 5.3 % of SLE patients) also appeared to
be consistent with previous studies of RA [8, 32], includ-
ing a reported prevalence of 16 % in 102 RA patients
(determined via interviews, and by checking past radio-
logical reports and chart review) [8]. However, Ørstavik
et al. [33] did suggest that, with the likely exception of
hip fractures, “non-vertebral fractures do not seem to
be a substantial burden in RA”.
With regard to factors that could cause/increase the
risks of fractures, RA on its own may be a risk factor
[5, 7, 34], although GC administration is also said to be
the leading cause of secondary osteoporosis [1]. Thus,
it is notable that Angeli et al. [21] concluded that RA
probably contributes to the risk of fractures, although
these researchers could not dissect the potential impact
of RA versus GC therapy on risk of fracture, while Van
Staa et al. [32] stated that the increased risk of fracture
is due to a combination of RA activity and GC therapy.
Indeed, inherent covariates make it difficult to attribute
an increased risk of fractures to GC usage in our study,
e.g. patients with morphometric vertebral fractures had
a statistically significantly longer time since menopause
than patients with an absence of these fractures. Simi-
larly, RA activity was higher in the presence of any self-
reported fractures than in their absence, although other
diseases affecting bone metabolism (e.g. secondary
amenorrhea, hyperthyroidism) were present in similar
proportions of patients (6.2–6.5 %) with and without
morphometric vertebral and self-reported non-vertebral
fractures. Thus, other diseases affecting bone metabol-
ism were unlikely to complicate these analyses.Both before and after adjusting for various covariates,
including age and RA and SLE diagnoses, patients with
any self-reported main non-vertebral fractures had a
higher cumulative GC dose than those without these
fractures. Thus, chronic GC therapy does appear to be as-
sociated with an increased risk of any self-reported main
non-vertebral fractures in our population of patients with
RA and/or SLE.4 These results are particularly significant
in terms of FRAX® as, at present, this tool does not con-
sider any potential impact of cumulative or current GC
dose on the risk of fracture, and only collects data about
whether or not the patient uses steroids. Therefore, pre-
dictions of fracture risk using FRAX® may be improved by
considering the chronicity and dosage of GC therapy. In
addition, the links between chronicity and dosage of GC
therapy and increased risk of non-vertebral fractures in
our study are similar to results in other publications
[35, 36] including an extensive meta-analysis [37].
Nevertheless, our results are inconclusive with regard
to any impact of cumulative GC dose on the risk of
sustaining a vertebral fracture. Conclusions also differ
between published studies as to whether or not cumu-
lative GC dose is associated with the risk of sustaining
a vertebral fracture [4, 21, 37, 38].
With regard to potential mechanism(s) linking GC ther-
apy with increased risk of nonvertebral fractures in our
study, it is possible that GC therapy does not only increase
fracture risk by reducing BMD [4, 21, 31, 39, 40], but also
by reducing bone quality through microarchitectural
changes [40]. This may explain why, in our study, a higher
proportion of patients suffered morphometric vertebral
fractures, and/or self-reported main non-vertebral frac-
tures, when taking treatments to reduce bone loss than
when not taking these treatments. Thus, ideally, prophy-
lactic treatments should be administered to improve bone
quality as well as quantity. Similarly, it may be prudent to
radiologically assess patients at high risk of vertebral frac-
tures, as recently done by Clark et al. [41], where high risk
patients were identified using a novel primary care-based
screening tool. The resulting radiological analyses could
be performed in conjunction with the Genant semiquanti-
tative method used in our study and other studies of RA
[8, 32] and SLE [10, 14, 22].
Our study does have some limitations. Firstly, no con-
trol group was included. Thus, direct comparisons of,
for instance, the prevalence of fractures could not be
made between patients using GCs versus those not using
GCs, and any indirect comparisons with other studies
are complicated by potential differences in study design
and patient populations. Secondly, all of the non-vertebral
fractures were only self-reported. Thirdly, higher propor-
tions of patients who had fractures were receiving medica-
tions to reduce bone loss, versus patients without fractures.
Thus, while these medications may have reduced the
Rentero et al. BMC Musculoskeletal Disorders  (2015) 16:300 Page 9 of 10prevalence of fractures, and may be regarded as a limita-
tion when determining the prevalence of fractures in
patients with RA/SLE, this was in a real-world clinical
population. Moreover, our study does have several
strengths, including a large sample size relative to compar-
able studies [7, 8, 12, 13, 33], and centralized reading of the
X-rays with uniform criteria that was likely to limit vari-
ability in the dataset. This thorough approach is likely to
have increased the accuracy of the estimated prevalence of
vertebral fractures, thus allowing more accurate determin-
ation of the impact of these fractures on patients’ physical
functioning and overall QoL.Conclusions
In summary, we detected a higher rate of vertebral
fractures in women with RA and/or SLE, chronically
treated with GCs, in centrally assessed X-rays when
compared with self-reported fractures. Moreover, verte-
bral and non-vertebral fractures appeared to be very
prevalent in these patients. Our results also suggest that
non-vertebral fractures may be related to chronic GC
use, rather than solely due to underlying disease. How-
ever, our results are inconclusive with regard to any
impact of cumulative GC dose on the risk of sustaining
a vertebral fracture. In addition, vertebral and non-
vertebral fractures had negative impacts upon QoL,
particularly physical functioning, and increased the risk
of further fractures in a 10-year period. It is therefore
important to carefully monitor patients with RA and/or
SLE who receive chronic GC therapy, to detect frac-
tures including morphometric vertebral fractures. Also,
in our opinion, physicians should implement preventa-
tive measures in patients with RA or SLE who receive
chronic GC therapy, to decrease the risk of sustaining
vertebral and non-vertebral fractures.Endnotes
1The institutional review boards for the 28 study sites
were: Hospital de Lugo, Lugo; Hospital Puerta del Mar,
Cádiz; Hospital Sanitas La Moraleja, Madrid; Hospital
Universitario Puerta de Hierro Majadahonda, Madrid;
Hospital Virgen del Puerto, Plasencia; Hospital Virgen
de la Macarena, Sevilla; Hospital Universitario de
Salamanca, Salamanca.
2It was not an a priori objective of this study to
compare the prevalence of fractures in patients with RA
versus patients with SLE.
3The selected baseline variables were: age, BMI,
menopausal status, diagnosis (RA and/or SLE), presence
of disease affecting bone metabolism, exposure to
therapies associated with risk of fracture, current GC
dose, smoking status, and whether the patient’s parent
had sustained a hip fracture.4These analyses were not performed separately for RA
or SLE subgroups, as these analyses were not planned,
and SLE subgroup analysis could not be done retrospectively
due to the small number of SLE patients.
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